The present-day treatment for cardiac arrhythmias: comparison of drug and non-drug options
DOI: https://doi.org/10.29296/25877305-2020-04-05
Issue:
4
Year:
2020
The present-day treatment of cardiac arrhythmias is performed using drug and non-drug options. Their role substantially varies in the treatment of individual types of cardiac arrhythmias. Based on the clinical recommendations published in 2019–2020, the author discusses the choice of medical tactics in typical clinical situations. The paper considers the results of the most important randomized trials (CASTLE-AF, CABANA, etc.) devoted to the impact of drug treatment and catheter ablation on clinical outcomes in patients with the most common persistent cardiac arrhythmia - atrial fibrillation (AF). It also presents the possibilities of an integrated patient-oriented approach to antiarrhythmic therapy for AF.
Keywords:
cardiology
cardiac arrhythmias
antiarrhythmic drugs
catheter ablation
atrial fibrillation
ventricular arrhythmias
paroxysmal supraventricular tachycardia
References:
- Bassil G., Markowitz S., Liu C. et al. Robotics for catheter ablation of cardiac arrhythmias: Current technologies and practical approaches // J. Cardiovasc. Electrophysiol. – 2020; 31 (3): 739–52. DOI: 10.1111/jce.14380
- Bennett R., Campbell T., Kumar S. Catheter and Device Management of Inherited Cardiac Conditions // Heart Lung Circ. – 2020; 29 (4): 594–606. DOI: 10.1016/j.hlc.2019.12.009
- Lei M., Wu L., Terrar D. et al. Modernized Classification of Cardiac Antiarrhythmic Drugs // Circulation. – 2018; 138 (17): 1879–96. DOI: 10.1161/CIRCULATIONAHA.118.035455
- Cronin E., Bogun F., Maury P. et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary // J. Arrhythm. – 2020; 36 (1): 1–58. DOI: 10.1002/joa3.12264
- Santangeli P., Marchlinski F. Ablation Therapy for Refractory Ventricular Arrhythmias // Annu. Rev. Med. – 2020; 71: 177–90. DOI: 10.1146/annurev-med-041818-020033
- Towbin J., McKenna W., Abrams D. et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy // Heart Rhythm. – 2019; 16 (11): e301–72. DOI: 10.1016/j.hrthm.2019.05.007
- Willems S., Tilz R., Steven D. et al. Preventive or Deferred Ablation of Ventricular Tachycardia in Patients with Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial // Circulation. – 2020; 141 (13): 1057–67. DOI: 10.1161/CIRCULATIONAHA.119.043400.
- Rizzo A., de Asmundis C., Brugada P. et al. Ablation for the treatment of Brugada syndrome: current status and future prospects // Expert Rev. Med. Devices. – 2020; 17 (2): 123–30. DOI: 10.1080/17434440.2020.1719831
- Bennett R., Campbell T., Kumar S. Catheter and Device Management ofInherited Cardiac Conditions // Heart Lung Circ. – 2020; 29 (4): 594–606. DOI: 10.1016/j.hlc.2019.12.009
- Ortmans S., Daval C., Aguilar M. et al. Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts // Expert Opin. Pharmacother. – 2019; 20 (17): 2101–14. DOI: 10.1080/14656566.2019.1669561
- Brugada J., Katritsis D., Arbelo E. et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) // Eur. Heart J. – 2020; 41 (5): 655–720. DOI: 10.1093/eurheartj/ehz467
- Zylla M., Brachmann J., Lewalter T. et al. Symptomatic arrhythmias after catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT): results from the German Ablation Registry // Clin. Res. Cardiol. – 2019 Nov 29. DOI: 10.1007/s00392-019-01576-x. [Epub ahead of print]
- Rottner L., Bellmann B., Lin T. et al. CatheterAblationofAtrial Fibrillation: State of the Art and Future Perspectives // Cardiol. Ther. – 2020 Jan 2. DOI: 10.1007/s40119-019-00158-2. [Epub ahead of print]
- Marrouche N., Brachmann J., Andresen D. et al. Catheter Ablation for Atrial Fibrillation with Heart Failure // N. Engl. J. Med. – 2018; 378 (5): 417–27. DOI: 10.1056/NEJMoa1707855
- Packer D., Mark D., Robb R. et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design // Am. Heart J. – 2018; 199: 192–9. DOI: 10.1016/j.ahj.2018.02.015
- Packer D., Mark D., Robb R. et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial // JAMA. – 2019; 321 (13): 1261–74. DOI: 10.1001/jama.2019.0693
- Balabanski T., Brugada J., Arbelo E. et al. Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry // Europace. – 2019; 21 (12): 1802–8. DOI: 10.1093/europace/euz216. [Epub ahead of print]
- Mark D., Anstrom K., Sheng S. et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial // JAMA. – 2019; 321 (13): 1275–85. DOI: 10.1001/jama.2019.0692
- Dan G. Rhythm Control in AF: Have We Reached the Last Frontier? // Eur. Cardiol. – 2019; 14 (2): 77–81. DOI: 10.15420/ecr.2019.8.1
- Cheng E., Liu C., Yeo I. et al.Risk of Mortality Following CatheterAblation of Atrial Fibrillation // J. Am. Coll. Cardiol. – 2019; 74 (18): 2254–64. DOI: 10.1016/j.jacc.2019.08.1036
- Wyse D., Waldo A., DiMarco J. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. – 2002; 347 (23): 1825–33.
- January C., Wann L., Calkins H. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society // J. Am. Coll. Cardiol. – 2019; 74 (1): 104–32. DOI: 10.1016/j.jacc.2019.01.011
- Reese-Petersen A., Olesen M., Karsdal M. et al. Atrial Fibrillationand Cardiac Fibrosis: A Review on the Potential of Extracellular Matrix Proteins as Biomarkers // Matrix Biol. – 2020; pii: S0945-053X(20)30026-3. DOI: 10.1016/j.matbio.2020.03.005. [Epub ahead of print]
- Prabhu S., Costello B., Taylor A. et al. Regression of Diffuse Ventricular FibrosisFollowing Restoration of SinusRhythm With Catheter Ablation inPatients With Atrial Fibrillation andSystolic Dysfunction: A Substudy of the CAMERA MRI Trial // JACC. Clin. Electrophysiol. – 2018; 4 (8): 999–1007. DOI: 10.1016/j.jacep.2018.04.013
- Park J., Yu H., Kim T. et al. Atrial Fibrillation Catheter Ablation Increases the Left Atrial Pressure // Circ. Arrhythm. Electrophysiol. – 2019; 12 (4): e007073. DOI: 10.1161/CIRCEP.118.007073
- Packer M. Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation // Eur. Heart J. – 2019; 40 (23): 1873–9. DOI: 10.1093/eurheartj/ehz284
- Zelniker T., Bonaca M., Furtado R. et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial // Circulation. – 2020; 141 (15): 1227–34. DOI: 10.1161/CIRCULATIONAHA.119.044183
- Hamilton D., Nandkeolyar S., Lan H. et al. Amiodarone: A Comprehensive Guide for Clinicians // Am. J. Cardiovasc. Drugs. – 2020 Mar 13. DOI: 10.1007/s40256-020-00401-5. [Epub ahead of print]
- Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation // Cochrane Database Syst. Rev. – 2019; 9: CD005049. DOI: 10.1002/14651858.CD005049.pub5
- Rouini M., Afshar M. Effect of CYP2D6 polymorphisms on the pharmacokinetics ofpropafenoneand its two main metabolites // Therapie. –2017; 72 (3): 373–82. DOI: 10.1016/j.therap.2016.10.005
- Pantlin P., Bober R., Bernard M. et al.Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease // J. Cardiovasc. Electrophysiol. – 2020; 31 (3): 607–11. DOI: 10.1111/jce.14335
- Kipp R., Askari M., Fan J. et al. Real-World Comparison of ClassesICandIII Antiarrhythmic Drugs asan Initial Rhythm Control Strategy inNewly Diagnosed Atrial Fibrillation: From the TREAT-AF Study // JACC. Clin. Electrophysiol. – 2019; 5 (2): 231–41. DOI: 10.1016/j.jacep.2018.08.025
- Dan G., Martinez-Rubio A., Agewall S. et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP) // Europace. – 2018; 20 (5): 731-2an. DOI: 10.1093/europace/eux373
- Kanorskij S.G. Antiaritmicheskaja terapija u bol'nyh s paroksizmal'noj i persistirujuschej formami fibrilljatsii predserdij: opredelenie dostizhimoj tseli i otsenka imejuschihsja sredstv // Kardiologija.– 2014; 54 (2): 70–4 [Kanorsky S.G. Antiarrhythmic Therapy in Patients With Paroxysmal and Persistent Atrial Fibrillation: Identification of Achievable Goals and Assessment of Available Funds // Kardiologiya.– 2014; 54 (2): 70–4 (in Russ.)].
- Kotecha D., Breithardt G., Camm A. et al. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference // Europace. –2018; 20 (3): 395–407. DOI: 10.1093/europace/eux318
- Duytschaever M., Demolder A., Phlips T. et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial // Eur. Heart J. – 2018; 39 (16): 1429–37. DOI: 10.1093/eurheartj/ehx666
- Shantha G., Alyesh D., Ghanbari H. et al.Antiarrhythmic drug therapy and all-cause mortality after catheter ablation of atrial fibrillation: Apropensity-matched analysis // Heart Rhythm. – 2019; 16 (9): 1368–73. DOI: 10.1016/j.hrthm.2019.06.007
- Hendriks J., Tieleman R., Vrijhoef H. et al. Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial // Europace. – 2019; 21 (12): 1785–92. DOI: 10.1093/europace/euz209. [Epub ahead of print]
- Chung M., Eckhardt L., Chen L. et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association // Circulation. – 2020; 141 (16): e750–72. DOI: 10.1161/CIR.0000000000000748
- Qin M., Zeng C., Liu X. The cardiac autonomic nervous system: A target for modulation of atrial fibrillation // Clin. Cardiol. –2019; 42 (6): 644–52. DOI: 10.1002/clc.23190